Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

GSVA: gene set variation analysis for microarray and RNA-Seq data

Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440

Molecular signatures database (MSigDB) 3.0

Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

The EMBL-EBI search and sequence analysis tools APIs in 2019

Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167

T cell exhaustion

Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448

Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease

Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851

Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms

Rőszer, T. (2015) · Mediators of Inflammation · doi:10.1155/2015/816460 · Cited by 1,762

TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes

Sanford, L. P., Ormsby, I., Groot, A. C. G.-D., Sariola, H., Friedman, R., Boivin, G. P., Cardell, E. L., & Doetschman, T. (1997) · Development · doi:10.1242/dev.124.13.2659 · Cited by 1,447

Latent TGF-β structure and activation

Shi, M., Zhu, J., Wang, R., Chen, X., Mi, L., Walz, T., & Springer, T. A. (2011) · Nature · doi:10.1038/nature10152 · Cited by 1,013

Transforming growth factor–β3 is required for secondary palate fusion

Proetzel, G., Pawlowski, S. A., Wiles, M. V., Yin, M., Boivin, G. P., Howles, P. N., Ding, J., Ferguson, M. W. J., & Doetschman, T. (1995) · Nature Genetics · doi:10.1038/ng1295-409 · Cited by 908

Hydrogen exchange mass spectrometry for the analysis of protein dynamics

Wales, T. E., & Engen, J. R. (2005) · Mass Spectrometry Reviews · doi:10.1002/mas.20064 · Cited by 864

Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms

Li, M. O., Sanjabi, S., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.011 · Cited by 794

T Cell-Produced Transforming Growth Factor-β1 Controls T Cell Tolerance and Regulates Th1- and Th17-Cell Differentiation

Li, M. O., Wan, Y. Y., & Flavell, R. A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.014 · Cited by 769

The UCSC Xena platform for public and private cancer genomics data visualization and interpretationPreprint

Goldman, M., Craft, B., Hastie, M., Repečka, K., Kamath, A., McDade, F., Rogers, D., Brooks, A. N., Zhu, J., & Haussler, D. H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/326470 · Cited by 608

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Lahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 571

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 502

The detection, correlation, and comparison of peptide precursor and product ions from data independent LC‐MS with data dependant LC‐MS/MS

Geromanos, S. J., Vissers, J. P. C., Silva, J. C., Dorschel, C. A., Li, G., Gorenstein, M. V., Bateman, R. H., & Langridge, J. (2009) · PROTEOMICS · doi:10.1002/pmic.200800562 · Cited by 499

Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm

Lindsay, M. E., Schepers, D., Bolar, N. A., Doyle, J. J., Gallo, E. M., Fert‐Bober, J., Kempers, M. J. E., Fishman, E. K., Chen, Y., Myers, L. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2349 · Cited by 495

Latent TGF-β-binding proteins

Robertson, I. B., Horiguchi, M., Zilberberg, L., Dabovic, B., Hadjiolova, K., & Rifkin, D. B. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.05.005 · Cited by 491

Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487

GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3 + regulatory T cells

Tran, D. Q., Andersson, J., Wang, R., Ramsey, H. E., Unutmaz, D., & Shevach, E. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901944106 · Cited by 473

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471

Regulatory mutations in transforming growth factor-?3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1

Beffagna, G., Occhi, G., Nava, A. K., Vitiello, L., Ditadi, A., Basso, C., Bauce, B., Carraro, G., Thiene, G., & Towbin, J. A. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.10.005 · Cited by 433

TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome

National Heart, L., Boileau, C., Guo, D.-C., Hanna, N., Regalado, E. S., Detaint, D., Gong, L., Varret, M., Prakash, S. K., Li, A. H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2348 · Cited by 382

The Utility of Hydrogen/Deuterium Exchange Mass Spectrometry in Biopharmaceutical Comparability Studies

Houde, D. J., Berkowitz, S. A., & Engen, J. R. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22432 · Cited by 379

The role of proteases in transforming growth factor-β activation

Jenkins, G. R. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.11.026 · Cited by 374

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

Lau, J., Cheung, J., Navarro, A., Lianoglou, S., Haley, B., Tótpál, K., Sanders, L., Koeppen, H., Caplazi, P., McBride, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14572 · Cited by 369

High-Speed and High-Resolution UPLC Separation at Zero Degrees Celsius

Wales, T. E., Fadgen, K. E., Gerhardt, G. C., & Engen, J. R. (2008) · Analytical Chemistry · doi:10.1021/ac8008862 · Cited by 353

Mutations in a TGF-β Ligand, TGFB3, Cause Syndromic Aortic Aneurysms and Dissections

Bertoli‐Avella, A. M., Gillis, E., Morisaki, H., Verhagen, J. M. A., de Graaf, B. M., van de Beek, G., Gallo, E. M., Kruithof, B. P. T., Venselaar, H., Myers, L. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.040 · Cited by 311

The α v β 1 integrin plays a critical in vivo role in tissue fibrosis

Reed, N. I., Jo, H., Chen, C., Tsujino, K., Arnold, T. D., DeGrado, W. F., & Sheppard, D. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5094 · Cited by 311

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0246-z · Cited by 294

Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311416259 · Cited by 284

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273

Force interacts with macromolecular structure in activation of TGF-β

Dong, X., Zhao, B., Iacob, R. E., Zhu, J., Koksal, A. C., Lu, C., Engen, J. R., & Springer, T. A. (2017) · Nature · doi:10.1038/nature21035 · Cited by 273

A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody

Angal, S., King, D. J., Bodmer, M., Turner, A. V., Lawson, A. D. G., Roberts, G., Pedley, B. R., & Adair, J. R. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90432-b · Cited by 245

Mice that lack activity of αvβ6- and αvβ8-integrins reproduce the abnormalities of Tgfb1 - and Tgfb3 -null mice

Aluwihare, P., Mu, Z., Zhao, Z., Yu, D., Weinreb, P. H., Horan, G. S. B., Violette, S. M., & Munger, J. S. (2008) · Journal of Cell Science · doi:10.1242/jcs.035246 · Cited by 229

Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors

Cassetta, L., & Kitamura, T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00038 · Cited by 200

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Meric-Bernstam, F., Sandhu, S. K., Hamid, O., Spreafico, A., Kasper, S., Dummer, R., Shimizu, T., Steeghs, N., Lewis, N., Talluto, C. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2507 · Cited by 190

GARP regulates the bioavailability and activation of TGFβ

Wang, R., Zhu, J., Dong, X., Shi, M., Lu, C., & Springer, T. A. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-12-1018 · Cited by 188

A Milieu Molecule for TGF-β Required for Microglia Function in the Nervous System

Qin, Y., Garrison, B. S., Ma, W., Wang, R., Jiang, A., Li, J., Mistry, M., Bronson, R. T., Santoro, D., Franco, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.027 · Cited by 180

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo

Cuende, J., Liénart, S., Dedobbeleer, O., van der Woning, B., De Boeck, G., Stockis, J., Huygens, C., Colau, D., Somja, J., Delvenne, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1983 · Cited by 155

Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules

Teschendorff, A. E., Gómez, S., Arenas, À., El‐Ashry, D., Schmidt, M., Gehrmann, M. C., & Caldas, C. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-604 · Cited by 152

Function-blocking Integrin αvβ6 Monoclonal Antibodies

Weinreb, P. H., Simon, K. J., Rayhorn, P., Yang, W. J., Leone, D. R., Dolinski, B. M., Pearse, B. R., Yokota, Y., Kawakatsu, H., Atakilit, A., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312103200 · Cited by 149

Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-β during Murine Colitis

Lee, C., Kwak, Y., Yang, T., Han, J. H., Park, S., Ye, M. B., Lee, W., Sim, K.-Y., Kang, J., Kim, Y., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.062 · Cited by 142

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A. M., Carlino, M. S., Grob, J., Kim, T. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.108 · Cited by 132

Integrin αvβ8–expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells

Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119

Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8

Stockis, J., Liénart, S., Colau, D., Collignon, A., Nishimura, S. L., Sheppard, D., Coulie, P. G., & Lucas, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710680114 · Cited by 111

Transforming growth factor beta signaling in adult cardiovascular diseases and repair

Doetschman, T., Barnett, J. V., Runyan, R. B., Camenisch, T. D., Heimark, R. L., Granzier, H. L. M., Conway, S. J., & Azhar, M. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1241-3 · Cited by 104

Glioblastoma Angiogenesis and Tumor Cell Invasiveness Are Differentially Regulated by β8 Integrin

Tchaicha, J. H., Reyes, S. B., Shin, J., Hossain, M. G., Lang, F. F., & McCarty, J. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0991 · Cited by 95

Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment

Gonzàlez-Juncà, A., Driscoll, K. E., Pellicciotta, I., Du, S., Lo, C. H., Roy, R., Parry, R., Tenvooren, I., Marquez, D. M., Spitzer, M. H., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0310 · Cited by 91

Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease

Minagawa, S., Lou, J., Seed, R. I., Cormier, A., Wu, S., Cheng, Y., Murray, L., Tsui, P., Connor, J., Herbst, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008074 · Cited by 90

Antibody Targeting of TGF-β in Cancer Patients

Lonning, S. M., Mannick, J. B., & McPherson, J. M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798808392 · Cited by 84

Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Gueorguieva, I., Cleverly, A., Stauber, A. J., Pillay, N. S., Rodon, J. A., Miles, C., Yingling, J. M., & Lahn, M. M. F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12256 · Cited by 78

Thoracic aortic-aneurysm and dissection in association with significant mitral valve disease caused by mutations in TGFB2

Renard, M., Callewaert, B. L., Malfait, F., Campens, L., Sharif, S., Campo, M. D., Valenzuela, I., McWilliam, C. A., Coucke, P. J., Paepe, A. D., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.029 · Cited by 68

Nuclear Factor I-C Links Platelet-Derived Growth Factor and Transforming Growth Factor β1 Signaling to Skin Wound Healing Progression

Plasari, G., Calabrese, A., Dusserre, Y., Gronostajski, R. M., Mcnair, A., Michalik, L., & Mermod, N. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01921-08 · Cited by 62

TGFβ signaling and congenital heart disease: Insights from mouse studies

Arthur, H. M., & Bamforth, S. D. (2011) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.20794 · Cited by 51

Overexpression of human transforming growth factor-β1 using a recombinant CHO cell expression system

Zou, Z., & Sun, P. D. (2004) · Protein Expression and Purification · doi:10.1016/j.pep.2003.06.001 · Cited by 48

Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms

Bedinger, D., Lao, L., Khan, S., Lee, S., Takeuchi, T., & Mirza, A. M. (2016) · mAbs · doi:10.1080/19420862.2015.1115166 · Cited by 42

TGF-β signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome

Joyce, C. E., Saadatpour, A., Ruiz‐Gutierrez, M., Bölükbaşı, Ö. V., Jiang, L., Thomas, D. D., Young, S., Hofmann, I., Sieff, C. A., Myers, K. C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125375 · Cited by 34

Nonclinical Safety Evaluation of a Transforming Growth Factor β Receptor I Kinase Inhibitor in Fischer 344 Rats and Beagle Dogs

Stauber, A. J. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.196 · Cited by 31

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.

Siefker-Radtke, A. O., Fishman, M., Balar, A. V., Grignani, G., Diab, A. K., Gao, J., Tagliaferri, M. A., Hannah, A. L., Karski, E. E., Zalevsky, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.388 · Cited by 22

Transforming Growth Factor Beta-2 Mutations in Barlow’s Disease and Aortic Dilatation

Disha, K., Schulz, S., Kuntze, T., & Girdauskas, E. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.01.103 · Cited by 8

ScholarRock/Martin-et-al-STM-2020 v0.1

Martin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C., Nikiforov, A., Danehy, F. T., et al. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3698168 · Cited by 1

TGF-β signaling in health, disease and therapeutics

Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,360

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 500

Resistance Mechanisms to Anti-PD Cancer Immunotherapy

Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468

Novel therapies emerging in oncology to target the TGF‐β pathway

Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28

Abstract 4090: Defeating primary checkpoint resistance: SRTβ1-Ab3 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1

Schürpf, T., Martin, C. J., Littlefield, C., Chapron, C., Wawersik, S., Kalra, A. V., Simpson, A., Danehy, F. T., Boston, C., Nikiforov, A., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-4090

TGFβ1-specific antibody spurs anti-tumour immunity

Cully, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00058-4 · Cited by 2

773 SOF10, selectively blocking latent TGF-β1 activation, potentiates the efficacy of checkpoint blockade therapy by modulating CAF dynamics and T cell infiltration

Sato, I., Kanamori, M., Nakagawa, K., Sun, S., Asanuma, K., Kawauchi, H., Kayukawa, Y., Matsuo, S., Shida-Kawazoe, M., Kashiwagi, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-sitc2024.0773 · Cited by 1

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

Yap, T. A., Barve, M. A., Gainor, J. F., Weekes, C. D., Bockorny, B., Ju, Y., Faucette, R., Bilic, S., Lee-Hoeflich, S. T., Song, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps3146 · Cited by 7